{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:44:38Z","timestamp":1781174678506,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Genetics and Cytogenetics"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.cancergencyto.2006.11.015","type":"journal-article","created":{"date-parts":[[2007,4,22]],"date-time":"2007-04-22T11:09:32Z","timestamp":1177240172000},"page":"89-99","source":"Crossref","is-referenced-by-count":25,"title":["Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark"],"prefix":"10.1016","volume":"174","author":[{"given":"Jacob H.","family":"Christensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Plesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Nibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne G.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte B.","family":"Kerndrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergencyto.2006.11.015_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.7326\/0003-4819-124-2-199601150-00004","article-title":"Interferon-\u03b1 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma: a randomized, controlled trial","volume":"124","author":"Hjorth","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib3","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib5","first-page":"7","article-title":"Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study","volume":"95","author":"Lenhoff","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib6","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1080\/10428190412331283224","article-title":"Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myeloma","volume":"45","author":"Depil","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib7","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2005-05-1981","article-title":"Relationship of patient survival and chromosome anomalies detected in metaphase and\/or interphase cells at diagnosis of myeloma","volume":"106","author":"Dewald","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/10428199909169625","article-title":"Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma","volume":"35","author":"Fonseca","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib9","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ijc.20491","article-title":"Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients","volume":"112","author":"Garc\u00eda-Sanz","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-2141.2000.02007.x","article-title":"Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance","volume":"109","author":"Hoechtlen-Vollmar","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1200\/JCO.2000.18.4.804","article-title":"Predictive role of interphase cytogenetics for survival of patients with multiple myeloma","volume":"18","author":"Konigsberg","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib12","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1182\/blood.V85.9.2490.bloodjournal8592490","article-title":"Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis","volume":"85","author":"Lai","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/sj.bmt.1701943","article-title":"Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma","volume":"24","author":"Rajkumar","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib14","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.V95.6.1925","article-title":"Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization","volume":"95","author":"Zojer","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib15","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2004-04-1319","article-title":"Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma","volume":"104","author":"Guti\u00e9rrez","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2004.1.237","article-title":"Multiple myeloma","author":"Harousseau","year":"2004","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib17","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","article-title":"Chromosome 13 abnormalities identified by FISH analysis and serum \u03b22-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy","volume":"97","author":"Facon","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib18","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V96.4.1505","article-title":"High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH","volume":"96","author":"Shaughnessy","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","article-title":"p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation","volume":"105","author":"Chang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib20","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"Smadja","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","article-title":"Intergroupe Francophone du My\u00e9lome. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy","volume":"100","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.yexcr.2004.11.012","article-title":"Cell responses to FGFR3 signalling: growth, differentiation and apoptosis","volume":"304","author":"L'H\u00f4te","year":"2005","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib24","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/sj.leu.2403347","article-title":"Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074","volume":"18","author":"Grand","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib25","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/blood-2004-10-3913","article-title":"CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma","volume":"105","author":"Trudel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib26","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2005-10-4179","article-title":"The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells","volume":"107","author":"Trudel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0165-4608(01)00388-0","article-title":"Cytogenetic aberrations in adult acute lymphocytic leukemia: optimal technique may influence the results","volume":"128","author":"Pedersen","year":"2001","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib28","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib29","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.V99.6.2185","article-title":"Intergroupe Francophone du My\u00e9lome. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation","volume":"99","author":"Avet-Loiseau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib30","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood.V88.5.1568.1568","article-title":"Frequent somatic deletion of the 13q12.3 locus encompassing BRCA2 in chronic lymphocytic leukemia","volume":"88","author":"Garcia-Marco","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib31","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.leu.2402125","article-title":"Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy","volume":"15","author":"Fonseca","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1365-2141.1999.01615.x","article-title":"P53 deletion is not a frequent event in multiple myeloma","volume":"106","author":"Avet-Loiseau","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib33","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V92.3.802","article-title":"Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy","volume":"92","author":"Drach","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib34","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib35","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.leu.2402797","article-title":"Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma","volume":"17","author":"Debes-Marun","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.leu.2403586","article-title":"Intergroupe Francophone du My\u00e9lome. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma","volume":"19","author":"Wuilleme","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2006.05.012","article-title":"Distinguishing primary and secondary translocations in multiple myeloma","author":"Gabrea","year":"2006","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib38","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2141.1997.2443061.x","article-title":"Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma","volume":"98","author":"Calasanz","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cancergencyto.2006.11.015_bib39","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1046\/j.1365-2141.2002.03757.x","article-title":"Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma","volume":"118","author":"Fassas","year":"2002","journal-title":"Br J Haematol"}],"container-title":["Cancer Genetics and Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460806007783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460806007783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T13:37:54Z","timestamp":1587476274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165460806007783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0165460806007783"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergencyto.2006.11.015","relation":{},"ISSN":["0165-4608"],"issn-type":[{"value":"0165-4608","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}